



**SASKATCHEWAN FORMULARY BULLETIN
UPDATE TO THE
59th EDITION OF THE
SASKATCHEWAN FORMULARY**

**NEW FULL FORMULARY
LISTINGS EFFECTIVE
DECEMBER 1, 2009:**

- Bimatoprost, ophthalmic solution, 0.01% (Lumigan-ALL)

**NEW EXCEPTION DRUG STATUS
LISTINGS EFFECTIVE
DECEMBER 1, 2009:**

- Calcium acetate, tablet, 667mg (PhosLo-FMC)

For treatment of:

- a) End-stage renal disease in patients intolerant to aluminum or calcium containing phosphate-binding agents.
- b) End-stage renal disease in patients where aluminum or calcium containing phosphate-binding agents are inappropriate.

- Interferon Beta-1A, pre-filled cartridge, 66mcg/1.5mL, (3 doses of 22 mcg), 132mcg/1.5mL (3 doses of 44mcg) (Rebif-SRO)

For coverage according to the current criteria for interferon Beta-1A.

- Trospium chloride, tablet, 20mg (Trosec-ORX)

For treatment of patients intolerant to oxybutynin chloride.

**REVISED EXCEPTION DRUG
STATUS CRITERIA EFFECTIVE
DECEMBER 1, 2009:**

- Tenofovir disoproxil fumarate, tablet, 300mg (Viread-GSK)

For treatment of:

- a) HIV in patients who have failed an alternative nucleoside reverse transcriptase inhibitor.
- b) HIV in patients intolerant to an alternative nucleoside reverse transcriptase inhibitor.

This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

c) Chronic hepatitis B infection in patients with cirrhosis documented on radiologic or histologic grounds and a HBV DNA concentration above 2000 IU/mL.

**NEW INTERCHANGEABLE FULL
FORMULARY OR EDS LISTINGS
EFFECTIVE NOVEMBER 1, 2009:**

- Azithromycin, oral suspension, 20mg/mL, 40mg/mL (Sandoz Azithromycin-SDZ)
- Fentanyl, transdermal system, 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr (Ran-Fentanyl Matrix-RAN)
- Nifedipine, extended release tablet, 60mg (Mylan-Nifedipine XL-MYL)
- Olanzapine, orally disintegrating tablet, 5mg, 10mg, 15mg (Novo-Olanzapine OD-NOP) (pms-Olanzapine ODT-PMS)
- Olanzapine, tablet, 2.5mg, 5mg, 7.5mg, 10mg, 15mg (Novo-Olanzapine-NOP) (pms-Olanzapine-PMS)
- Quetiapine, tablet, 25mg, 100mg, 200mg, 300mg (Jamp-Quetiapine-JPC)
- Salbutamol sulfate, metered dose inhaler, 100 mcg/dose (Ventolin HFA-GSK)
- Simvastatin, tablet, 5mg, 10mg, 20mg, 40mg, 80mg (Jamp-Simvastatin-JPC)

**DRUGS REVIEWED AND NOT
RECOMMENDED**

The Committee supports the CEDAC recommendation that the following products not be listed:

- Teriparatide (rDNA origin), pre-filled pen, 250mcg/mL (Forteo-LIL)
- Levodopa/carbidopa, intestinal gel, 20mg/mL/5mg/mL (Duodopa-SLV)

**RECOMMENDED FOR DELISTING
EFFECTIVE DECEMBER 1, 2009:**

- Flavoxate HCl, tablet, 200mg (Apo-Flavoxate-APX)

The Saskatchewan Formulary Committee (SFC) have recommended that Apo-Flavoxate 200mg be delisted from the Formulary due to the high cost of this drug relative to other listed alternatives and insufficient evidence to support continued listing of this product. For those patients currently taking the drug, coverage will continue i.e. they will be GRANDFATHERED.

**FROM THE ADVISORY
COMMITTEE ON INSTITUTIONAL
PHARMACY PRACTICE (ACIPP):**

- Fondaparinux sodium, injection, 2.5mg/0.5mL, 7.5mg/0.6mL (Arixtra-GSK)

For the treatment of heparin-induced thrombocytopenia (HITT).

Note: the brand name will not appear in the HBDL as only generic names are published in this list.